NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,806 | +25.2% | 13,507 | 0.0% | 0.00% | – |
| Q2 2023 | $7,835 | -89.9% | 13,507 | -60.7% | 0.00% | – |
| Q4 2022 | $77,595 | -53.8% | 34,334 | -32.1% | 0.00% | – |
| Q3 2022 | $168,000 | -85.6% | 50,583 | -82.1% | 0.00% | -100.0% |
| Q2 2022 | $1,167,000 | +203.9% | 283,269 | +311.4% | 0.00% | – |
| Q1 2022 | $384,000 | -63.6% | 68,860 | -7.6% | 0.00% | -100.0% |
| Q4 2021 | $1,054,000 | +66.8% | 74,543 | +121.9% | 0.00% | – |
| Q3 2021 | $632,000 | +1.0% | 33,591 | -4.7% | 0.00% | – |
| Q2 2021 | $626,000 | +25.5% | 35,262 | +35.9% | 0.00% | – |
| Q1 2021 | $499,000 | +55.9% | 25,956 | +51.9% | 0.00% | – |
| Q4 2020 | $320,000 | +27.5% | 17,093 | +16.8% | 0.00% | – |
| Q3 2020 | $251,000 | -30.9% | 14,634 | -1.5% | 0.00% | – |
| Q2 2020 | $363,000 | +190.4% | 14,860 | +102.7% | 0.00% | – |
| Q1 2020 | $125,000 | -94.5% | 7,331 | -93.1% | 0.00% | -100.0% |
| Q4 2019 | $2,281,000 | -16.9% | 105,643 | -29.9% | 0.00% | 0.0% |
| Q3 2019 | $2,746,000 | -56.6% | 150,746 | -15.2% | 0.00% | -60.0% |
| Q2 2019 | $6,323,000 | +18.7% | 177,727 | +12.1% | 0.01% | 0.0% |
| Q1 2019 | $5,327,000 | -26.5% | 158,543 | -28.1% | 0.01% | -28.6% |
| Q4 2018 | $7,247,000 | -49.6% | 220,539 | -6.5% | 0.01% | -36.4% |
| Q3 2018 | $14,376,000 | +114.2% | 235,825 | +71.5% | 0.01% | +83.3% |
| Q2 2018 | $6,713,000 | -39.7% | 137,491 | +31.3% | 0.01% | -40.0% |
| Q1 2018 | $11,129,000 | +2470.2% | 104,730 | +1344.2% | 0.01% | – |
| Q4 2017 | $433,000 | +127.9% | 7,252 | -8.4% | 0.00% | – |
| Q3 2017 | $190,000 | +31.0% | 7,914 | +7.0% | 0.00% | – |
| Q2 2017 | $145,000 | -24.5% | 7,395 | -9.8% | 0.00% | – |
| Q1 2017 | $192,000 | +131.3% | 8,195 | +21.8% | 0.00% | – |
| Q4 2016 | $83,000 | -24.5% | 6,731 | +5.3% | 0.00% | – |
| Q3 2016 | $110,000 | +25.0% | 6,395 | +3.4% | 0.00% | – |
| Q2 2016 | $88,000 | -15.4% | 6,187 | -18.4% | 0.00% | – |
| Q1 2016 | $104,000 | -8.0% | 7,581 | +12.9% | 0.00% | – |
| Q4 2015 | $113,000 | +156.8% | 6,712 | +66.8% | 0.00% | – |
| Q3 2015 | $44,000 | -77.1% | 4,024 | -76.9% | 0.00% | – |
| Q1 2015 | $192,000 | -35.6% | 17,425 | -9.4% | 0.00% | – |
| Q4 2014 | $298,000 | +626.8% | 19,230 | +500.9% | 0.00% | – |
| Q2 2014 | $41,000 | -88.3% | 3,200 | -90.4% | 0.00% | -100.0% |
| Q3 2013 | $350,000 | – | 33,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |